NURSl 5334/l NURS5334l Examl 1l –l
Advancedl Pharmacologyl Guidel |l UTAl
(Latestl 2026l Update)l 100%l Verifiedl
Questionsl &l Answersl |l Gradel A
Q:l Carbapenems
Answer:
Onlyl 4:l Imipenem,l Meropenem,l Ertrapenem,l Doripenem
EXTREMELYl broadl spectrum,l **onlyl givenl IV**
notl activel againstl MRSA
Q:l Iminpenem-cilastatin
Answer:
Mostl effectivel antibioticl againstl anaerobicl bacteria
Highlyl effectivel againstl Graml (+/)l coccil &l bacilli
Q:l Meropenem
Answer:
Bacteriall meningitis-3ml andl up
Intraabdominall infectionsl acrossl ages
complicatedl skinl infections
Q:l Ertrapeneml (Invanz)
Answer:
Pelvicl infections
,Communityl acquiredl pneumonia
Complicatedl UTIs
Abdomen/skinl infections
Q:l Vancomycinl treats
Answer:
graml positive-l staphl aureus/epiderm,l c.diff
Q:l Vancomycinl AE
Answer:
ototoxicity,l nephrotoxicity,l redl manl syndrome
Q:l Vancomycinl mainl danger
Answer:
Hosp/vent.l pneumonial inl ptl w/l Crcll lessl thanl 50l asl itl increasesl mortality
Q:l Monobactamsl treats
Answer:
graml negativel aerobic
Q:l Fosfomycinl treats
Answer:
Uncomplicatedl enterococcusl andl Ecolil UTI'sl inl womenl **singlel dosel therapy**
Q:l Aminoglycosides
, Answer:
gentamicin,l neomycin,l streptomycin,l amikacin
Q:l Aminoglycosidesl treat
Answer:
graml negativel bacilli
Pseudomonas,l eccoli,l Klebsiella,l serrata,l p.mirabilis.
**Notl effectivel againstl anaerobicl microbes**
Q:l Aminoglycosidesl (BBW)
Answer:
ototoxicityl andl nephrotoxicity
neuromuscularl transmissionl causingl flaccidityl andl lifel threateningl paralysisl **reversedl
withl IVl calcium**
Q:l aminoglycosidesl peakl andl trough
Answer:
Peak:l 30l minl afterl IVl orl IMl (shouldl bel high)
Trough:l divided-l beforel nextl dose,l daily-1l hrl beforel nextl dosel (valuel shouldl bel low:l
likel zero)
Q:l Sulfonamidesl MOA
Answer:
inhibitl folicl acidl synthesis
Broadl spectrum
Bugsl theyl fight:l MRSA,l listeria,l chlamydia,l toxoplasmosel species
Q:l Sulfonamidesl adversel effects
Advancedl Pharmacologyl Guidel |l UTAl
(Latestl 2026l Update)l 100%l Verifiedl
Questionsl &l Answersl |l Gradel A
Q:l Carbapenems
Answer:
Onlyl 4:l Imipenem,l Meropenem,l Ertrapenem,l Doripenem
EXTREMELYl broadl spectrum,l **onlyl givenl IV**
notl activel againstl MRSA
Q:l Iminpenem-cilastatin
Answer:
Mostl effectivel antibioticl againstl anaerobicl bacteria
Highlyl effectivel againstl Graml (+/)l coccil &l bacilli
Q:l Meropenem
Answer:
Bacteriall meningitis-3ml andl up
Intraabdominall infectionsl acrossl ages
complicatedl skinl infections
Q:l Ertrapeneml (Invanz)
Answer:
Pelvicl infections
,Communityl acquiredl pneumonia
Complicatedl UTIs
Abdomen/skinl infections
Q:l Vancomycinl treats
Answer:
graml positive-l staphl aureus/epiderm,l c.diff
Q:l Vancomycinl AE
Answer:
ototoxicity,l nephrotoxicity,l redl manl syndrome
Q:l Vancomycinl mainl danger
Answer:
Hosp/vent.l pneumonial inl ptl w/l Crcll lessl thanl 50l asl itl increasesl mortality
Q:l Monobactamsl treats
Answer:
graml negativel aerobic
Q:l Fosfomycinl treats
Answer:
Uncomplicatedl enterococcusl andl Ecolil UTI'sl inl womenl **singlel dosel therapy**
Q:l Aminoglycosides
, Answer:
gentamicin,l neomycin,l streptomycin,l amikacin
Q:l Aminoglycosidesl treat
Answer:
graml negativel bacilli
Pseudomonas,l eccoli,l Klebsiella,l serrata,l p.mirabilis.
**Notl effectivel againstl anaerobicl microbes**
Q:l Aminoglycosidesl (BBW)
Answer:
ototoxicityl andl nephrotoxicity
neuromuscularl transmissionl causingl flaccidityl andl lifel threateningl paralysisl **reversedl
withl IVl calcium**
Q:l aminoglycosidesl peakl andl trough
Answer:
Peak:l 30l minl afterl IVl orl IMl (shouldl bel high)
Trough:l divided-l beforel nextl dose,l daily-1l hrl beforel nextl dosel (valuel shouldl bel low:l
likel zero)
Q:l Sulfonamidesl MOA
Answer:
inhibitl folicl acidl synthesis
Broadl spectrum
Bugsl theyl fight:l MRSA,l listeria,l chlamydia,l toxoplasmosel species
Q:l Sulfonamidesl adversel effects
